NEW YORK (GenomeWeb News) – Venaxis today announced it has submitted a 510(k) application to the US Food and Drug Administration to market its biomarker assay for identifying patients at low risk for appendicitis.

Venaxis added that it has requested concurrent de novo determination for the assay called the APPY1 Test. Earlier this month, the Castle Rock, Colo.-based company announced top-line results from the pivotal US study for the test, saying APPY1 had a negative predictive value of 97.3 percent, sensitivity of 96.9 percent, and specificity of 37.8 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.